A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy

UCI-17-90
NCT02500199
Cancer - Breast, Cancer - Colon, Cancer - Corpus Uteri, Cancer - Lung, Cancer - Stomach
Sai-Hong Ignatius Ou
Open
Treatment
I
Adult
National

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.